 |
| Date | Title | | | 09/01/10 | Gilead Provides Update on $5 Billion Stock Repurchase Program |  | | 08/19/10 | Gilead Sciences Announces Notification of ANDA Filing for Hepsera(R) | | | 07/30/10 | Gilead Closes Sale of $2.2 Billion of Convertible Senior Notes | | | 07/27/10 | Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock | | | 07/26/10 | Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock | | | 07/20/10 | Gilead Sciences Announces Second Quarter 2010 Financial Results | | | 07/14/10 | Gilead Sciences Files Patent Infringement Lawsuit Against Lupin Limited | | | 07/13/10 | Gilead Sciences to Release Second Quarter 2010 Financial Results on
Tuesday, July 20, 2010 | | | 06/25/10 | Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million | | | 06/18/10 | Gilead's Head-to-Head Study of Cayston(R)
Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients
Achieves Co-Primary Efficacy Endpoint of Non-Inferiority | | | 06/10/10 | Gilead Sciences Announces Notification of ANDA Filing for Ranexa(R) | | | 06/09/10 | Gilead Sciences to Present at Two Upcoming Investor Conferences | | | 06/08/10 | John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice
President, Liver Disease Therapeutics | | | 06/04/10 | Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs) | | | 06/02/10 | Gilead Sciences to Present at the Jefferies 2010 Global Life Sciences
Conference on Wednesday, June 9 | | | 05/27/10 | Gilead Sciences to Present at the Sanford C. Bernstein 26th
Annual Strategic Decisions Conference on Thursday, June 3 | | | 05/19/10 | Gilead Sciences to Present at the 2010 Citi Investment Research
Global Health Care Conference on Wednesday, May 26 | | | 05/11/10 | Gilead Announces $5 Billion Share Repurchase Program | | | 05/06/10 | Gilead Sciences to Present at the Banc of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13 | | | 04/27/10 | Gilead Finalizes Selection of Bioequivalent Formulation for the
Fixed-Dose Regimen of Truvada(R) and Tibotec
Pharmaceuticals' TMC278 | | | 04/20/10 | Gilead Sciences Announces Record First Quarter 2010 Financial Results | | | 04/20/10 | Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R)
and Tibotec Pharmaceuticals' TMC278 | | | 04/19/10 | Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With
Chronic Hepatitis C | | | 04/13/10 | Gilead Sciences to Release First Quarter 2010 Financial Results on
Tuesday, April 20, 2010 | | | 04/12/10 | Gilead Initiates Phase III Clinical Program Evaluating Single-Tablet,
Once-Daily "Quad" Regimen for HIV | | | 03/17/10 | Gilead Sciences to Present at the Barclays Capital 2010 Global
Healthcare Conference on Wednesday, March 24 | | | 03/04/10 | Gilead Sciences to Present at the Cowen and Company 30th
Annual Health Care Conference on Thursday, March 11 | | | 02/22/10 | U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa | | | 02/17/10 | Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of
Virologic Suppression in Phase II Study | | | 02/02/10 | Gilead Sciences to Present at the 12th Annual BIO CEO Investor Conference on Tuesday, February 9 | | | 01/29/10 | Gilead Announces Share Repurchase Program | | | 01/28/10 | Per Wold-Olsen Joins Gilead Sciences' Board of Directors | | | 01/27/10 | Gilead Sciences Announces Notification of ANDA Filing for Viread® | | | 01/26/10 | Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results | | | 01/19/10 | Gilead Sciences to Release Fourth Quarter and Year End 2009 Financial Results on Tuesday, January 26, 2010 | | | 01/06/10 | Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective | | | 01/04/10 | Gilead Sciences to Present at Two Upcoming Investor Conferences | |
|
|
The information in these news pages should not be deemed accurate or current except as of the date of the particular press release or posting. Gilead has no intention of updating and specifically disclaims any duty to update the information in the press releases. The press releases may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. | 
